INZY Inozyme Pharma, Inc. Gross Profit Rate

Official company branding of inozyme.com (INZY)

Inozyme Pharma, Inc. (INZY) is developing innovative enzymes for the therapy of rare mineralization disorders, leading the market in R&D. Business stability is based on the creation of unique treatment methods for genetic defects. A monopoly position allows the company to exercise pricing power over the life-saving molecule INZ-701. The gross margin rate clearly confirms this financial potential, and 0.00 records the magnitude of this parameter.

Inozyme Pharma (INZY): Gross Margin from 07/04/2022 to 07/12/2025

Analytical breakdowns and data insights for company Inozyme Pharma, Inc. (INZY)

- market value and analyst target forecast:
Basic company analysis:INZY Inozyme Pharma
Mass-produced product of Inozyme

The specific requirements for transporting drugs used to treat rare mineralization disorders necessitate costly climate control, which directly impacts the cost of goods sold for Inozyme Pharma, Inc. (INZY). This indicator measures the profit margin after deducting direct production costs, allowing for an assessment of operational management efficiency. Analyzing monthly gross margins helps investors strip away GAAP accounting distortions and determine the actual sustainability of the business's market value.